SNDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient trader. Despite longer-term bullish moving averages and very bullish options positioning, near-term momentum is weakening (negative/expanding MACD histogram), price is below the pivot (20.84), pattern-based odds lean slightly downside over the next day/week, and insider selling has surged. The better risk/reward entry is closer to support (19.90–19.32); at 20.41 the setup is not compelling enough to chase.
Trend/momentum: The moving average stack is bullish (SMA_5 > SMA_20 > SMA_200), suggesting the broader trend has been constructive. However, momentum is currently deteriorating: MACD histogram is -0.122 and negatively expanding, which often precedes additional weakness or at least a failed bounce.
RSI/overbought-oversold: RSI_6 = 38.45, leaning toward the lower end (soft/weak tape), but not a clean oversold reversal signal.
Key levels: Price 20.41 is below the pivot 20.84. Immediate support is S1 19.90, then S2 19.32. Resistance is R1 21.78 then R2 22.37. For an immediate buy, you would typically want confirmation back above the pivot and improving MACD; neither is present.
Short-horizon statistical read: Similar-pattern projection indicates ~70% odds of -1.68% next day, -0.7% next week, and roughly flat over a month (-0.11%), reinforcing that the current moment is not a high-conviction entry.
Intellectia Proprietary Trading Signals
Analyst commentary points to expectations for stronger growth into Q4/Q1 and mentions approval/traction drivers (e.g., NPM1 and better traction of Niktimvo per Barclays commentary). Options market positioning is notably bullish (very low put/call ratios) and activity is elevated, which can support upside if price reclaims the pivot and momentum turns.
Insiders are selling aggressively (selling amount up ~195% over the last month), which is a notable near-term sentiment/overhang. Technical momentum is weakening (negative and expanding MACD histogram) and price is below the pivot, increasing the odds of a test of 19.90–19.32 support. No fresh news in the past week to act as an immediate catalyst. Pattern-based forecast also tilts slightly negative over the next day/week.
Latest quarter: 2025/Q3. Revenue grew sharply to $45.87M (+266.97% YoY), indicating strong top-line momentum. However, profitability worsened: net income fell to -$60.72M (more negative; -27.83% YoY), and EPS declined to -0.70 (-28.57% YoY). Gross margin remained very high at 95.42% but slipped YoY (-4.58%), suggesting the business is scaling revenue but still burning meaningfully.
Street stance remains broadly constructive (Buy/Overweight cluster). Recent changes show mixed but net-positive target support: JPMorgan cut PT to $33 from $40 (still Overweight), UBS raised PT to $38 (Buy), and Barclays raised PT to $35 from $22 (Overweight) after management discussions (also an earlier bump to $22 from $19). Wall Street pros: expectation of improving growth/traction and favorable longer-term outlook. Cons: model trims from at least one major firm and the company is still loss-making, which can pressure the stock when momentum fades.
Influential/politician activity: No recent congress trading data available in the last 90 days; no politician activity provided.
